STATINS AND THEIR INTERACTION WITH MODEL CELL MEMBRANES ACCORDING TO THE DATA OF NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY

Aim. To study the location of pravastatin, simvastatin, fluvastatin and cerivastatin in molecular complexes with model cell membranes based on dodecylphosphocholine, and also to calculate the average interatomic distances between the atoms of statins and micelles. Material and methods. Nuclear magnetic resonance (NMR) spectroscopy was chosen as a method of study. NMR spectroscopy of the Overhauser nuclear effect (NOESY) is one of the most effective methods in the study of intermolecular interactions, in particular, in studies of drugs. Information on the spatial structure of the molecular complex, as well as on the fragments of molecules responsible for the effective interaction leading to complex formation, was obtained by NOESY spectroscopy. All NMR experiments were performed on a Bruker Avance II 500 spectrometer with a 5 mm zgradient inverse sensor with the TOPSPIN software. The calculation of the interatomic distances was made with an accuracy of 0.1 A. Results. The location of pravastatin, simvastatin, fluvastatin and cerivastatin in molecular complexes with model cell membranes based on dodecylphosphocholine was determined based on NMR NOESY experiments. The average interatomic distances between the atoms of statins and micelles were also calculated. Pravastatin weakly binds to the polar surface of the model membrane, while simvastatin penetrates into the space between the hydrocarbon chains of the micelle. Fluvastatin interacts mainly with model membranes by penetration of its aromatic fragments into the surface of the micelle. Cerivastatin has a unique arrangement in the model membrane. It is located deep in the hydrophobic nucleus of the micelle close to the terminal methylene group. Conclusion: Even minor differences in the chemical structure of statins lead to different patterns of interaction with model membranes. These differences can explain the characteristics of the pharmacological properties of these substances.

1. Vaughan C.J., Gotto A.M. Jr., Basson C.T. The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology. 2000;35:1-10.

2. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology & Therapeutics. 1999;84:413-28.

3. Thompson P.D., Panza G., Zaleski A., Taylor B. Statin-Associated Side Effects. Journal of the American College of Cardiology. 2016;67(20):2395-410.

4. Zhou Y.Y., Zhu G.Q., Wang Y., et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016;7(16):21753-62.

5. Chong P.H., Seeger J.D., Franklin C. Clinically Relevant Differences between the Statins: Implications for Therapeutic Selection. The American Journal of Medicine. 2001;111:390-400.

6. Mason R.P., Walter M.F., Day Ch.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. The American Journal of Cardiology. 2005;96:11-23.

7. Larocque G., Arnold A.A., Chartrand E., et al. Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids. European Biophysics Journal 2010;39:1637-47.

8. Mason R.P. Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. The American Journal of Cardiology. 2006;98:34P-41P.

9. Rakhmatullin I.Z., Galiullina L.F., Klochkova E.A., et al. Structural studies of pravastatin and simvastatin and their complexes with SDS micelles by NMR spectroscopy. Journal of Molecular Structure. 2016; 1105: 25-9.

10. Latfullin I.A., Galiullina L.F., Rakhmatullin I.Z., et al. Pleiotropic statins. Are there any possibilities for explaining the phenomenon? Rational Pharmacotherapy in Cardiology. 2015;11(6):634-7. (In Russ.) [Латфуллин И.А., Галиуллина Л.Ф., Рахматуллин И.З., и др. Плейотропность статинов. Имеются ли возможности объяснения феномена? Рациональная Фармакотерапия в Кардиологии. 2015;11(6):634-7].

11. Galiullina L.F., Rakhmatullin I.Z., Klochkova E.A., et al. Structure of pravastatin and its complex with sodium dodecyl sulfate micelles studied by NMR spectroscopy. Magnetic Resonance in Chemistry. 2015;53(2):110-4.

12. Galiullina L.F., Aganova O.V., Latfullin I.A., et al. NMR Study of conformational structure of fluvastatin and its complex with dodecylphosphocholine micelles. Bionanoscience. 2016;6:352-4.

13. Galiullina L.F., Aganova O.V., Latfullin I.A., et al. Interaction of different statins with model membranes by NMR data. BBA Biomembranes. 2017;1859:295-300.

14. Wagner R., Berger S. Gradient-selected NOESY - A fourfold reduction of the measurement time for the NOESY experiment. Journal of Magnetic Resonance, Series A. 1996;123:119-21.

15. Stott K., Stonehouse J., Keeler J. et al. Excitation sculpting in high-resolution nuclear magnetic resonance spectroscopy: application to selective NOE experiments. Journal of the American Chemical Society. 1995;117:4199-200.

16. Kessler H., Gehrke M., Grisenger C. Two-dimensional NMR spectroscopy: background and overview experiments. Angewandte Chemie International Edition. 1988;27(4):490-536.

17. Furberg C.D. Natural statins and stroke risk. Circulation. 1999;99:185-8.

18. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovascular Drugs and Therapy. 2003;17:265-85.

19. Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109:III50-7.

20. Davidson M.H. Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases. 2004;47:73-104.

21. Lindahl A., Sandstrom R., Ungell A.-L., Abrahamsson B., Knutson T.W., Knutson L., Lennerna H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology & Therapeutics. 1996;60:493-503.